Related Experiment Video
Updated: Jun 20, 2026
09:37
Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
Published on: August 25, 2021
Cancer cell apoptotic pathways mediated by PEDF: prospects for therapy
Matthew L Broadhead1, Crispin R Dass, Peter F M Choong
1Department of Orthopaedics and University of Melbourne Department of Surgery, St. Vincent's Hospital, VIC, Australia.
Trends in Molecular Medicine
|September 29, 2009
Summary
Pigment epithelium-derived factor (PEDF) shows anticancer promise by influencing apoptosis. Further research into PEDF
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- Pigment epithelium-derived factor (PEDF) exhibits antiangiogenic and antitumourigenic properties, suggesting its potential as an anticancer therapeutic.
- Understanding PEDF's role in the aberrant apoptotic pathways of cancer cells is crucial for its clinical application.
- Current research highlights the need for a comprehensive characterization of PEDF's mechanisms in cancer.
Purpose of the Study:
- To review known apoptotic pathways relevant to PEDF and cancer.
- To highlight a recently identified pathway involving the PEDF receptor, PPARgamma, and p53.
- To explore potential new therapeutic targets and strategies for cancer treatment based on PEDF's functions.
Main Methods:
- Literature review of scientific articles on PEDF, apoptosis, and cancer.
- Analysis of established and emerging molecular pathways implicated in cancer.
- Synthesis of current knowledge regarding PEDF's interactions with cellular components involved in apoptosis.
Main Results:
- PEDF's dual role in antiangiogenesis and antitumourigenesis is established.
- A novel apoptotic pathway involving PEDF receptor, PPARgamma, and p53 has been recently described.
- Characterization of these pathways is essential for understanding cancer biology.
Conclusions:
- PEDF holds significant promise as a targeted anticancer agent.
- Further elucidation of PEDF-mediated apoptotic pathways may reveal novel therapeutic targets.
- Targeted therapies based on PEDF could offer specificity and potentially reduce the side effects associated with conventional chemotherapy.
Related Concept Videos
01:31The Intrinsic Apoptotic Pathway
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
01:17The Extrinsic Apoptotic Pathway
The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
01:19Interactions Between Signaling Pathways
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...